Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2.
Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2.
复制标题
特定的 COVID-19 症状与 SARS-CoV-2 的高抗体水平相关。
DOI：
10.4049/immunohorizons.2100022
复制
发表时间：
2021-06-17
期刊：
影响因子：
--
通讯作者：
Shelef MA
中科院分区：
文献类型：
--
作者：
Amjadi MF;O'Connell SE;Armbrust T;Mergaert AM;Narpala SR;Halfmann PJ;Bashar SJ;Glover CR;Heffron AS;Taylor A;Flach B;O'Connor DH;Kawaoka Y;McDermott AB;Sethi AK;Shelef MA
持久的免疫力将是战胜新冠肺炎的关键。然而，与高滴度抗SARS-CoV-2抗体的发展相关的因素以及这些抗体持续多长时间仍未完全确定。特别是，对新冠肺炎症状和抗SARS-CoV-2抗体之间的关系的了解有限。为了解决这些未知的问题，我们用三种方法对不同临床类型的新冠肺炎恢复期患者在症状缓解后5周(n=113)和3个月(n=79)的血清中抗SARS-CoV-2抗体进行了定量：一种新的多重定量抗SARS-CoV-2四种抗原的免疫球蛋白的方法，一种新的SARS-CoV-2受体结合域-血管紧张素转换酶2抑制法，以及一种SARS-CoV-2中和试验。然后，我们确定了临床和人口统计学因素，包括以前从未评估过的新冠肺炎症状，这些因素与高抗SARS-CoV-2抗体水平一致相关。我们检测了98%的新冠肺炎康复者在症状缓解5周后检测到的抗SARS-CoV-2抗体，并且抗体水平在3个月后没有下降。疾病严重程度越高、年龄越大、男性、体重指数越高、Charlson共病指数得分越高，抗SARS-CoV-2抗体水平越高。此外，我们首次报告了新冠肺炎症状，最持续的发烧、身体疼痛和食欲不振，与较高的抗SARS-CoV-2抗体水平有关。我们的结果为抗SARS-CoV-2抗体的发展和持久性提供了强有力的新见解。
Lasting immunity will be critical for overcoming COVID-19. However, the factors associated with the development of high titers of anti-SARS-CoV-2 antibodies and how long those antibodies persist remain incompletely defined. In particular, an understanding of the relationship between COVID-19 symptoms and anti-SARS-CoV-2 antibodies is limited. To address these unknowns, we quantified serum anti-SARS-CoV-2 antibodies in clinically diverse COVID-19 convalescent human subjects five weeks (n=113) and three months (n=79) after symptom resolution with three methods: a novel multiplex assay to quantify IgG against four SARS-CoV-2 antigens, a new SARS-CoV-2 receptor binding domain-angiotensin converting enzyme 2 inhibition assay, and a SARS-CoV-2 neutralizing assay. We then identified clinical and demographic factors, including never before assessed COVID-19 symptoms, that consistently correlate with high anti-SARS-CoV-2 antibody levels. We detected anti-SARS-CoV-2 antibodies in 98% of COVID-19 convalescent subjects five weeks after symptom resolution and antibody levels did not decline at three months. Greater disease severity, older age, male sex, higher body mass index, and higher Charlson Comorbidity Index score correlated with increased anti-SARS-CoV-2 antibody levels. Moreover, we report for the first time that COVID-19 symptoms, most consistently fever, body aches, and low appetite, correlate with higher anti-SARS-CoV-2 antibody levels. Our results provide robust and new insights into the development and persistence of anti-SARS-CoV-2 antibodies.